Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion type Assertion NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_head.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion description "[Moreover, dominant negative cross talk between ectopic wild-type p53 and recently identified dominant p53 mutants and splice variants of p63 and p73--which are frequently overexpressed in ovarian cancers--could seriously compromise the effectiveness of p53 gene therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_provenance.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion evidence source_evidence_literature NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_provenance.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion SIO_000772 12850192 NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_provenance.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion wasDerivedFrom befree-20150227 NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_provenance.
- NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_assertion wasGeneratedBy ECO_0000203 NP767853.RATbgG6f3KfSRlikyMxvn3nEeDRV-P14msxTwvMUL1G08130_provenance.